Myriad Genetics First Quarter 2026 Financial Earnings

5/5/2026 | 1:30 pm PST / 4:30pm EST

Webcast Link
View Presentation

Events & Presentations

  • Myriad Genetics First Quarter 2026 Financial Earnings

    05/05/2026 | 1:30pm PDT / 4:30pm EDT

    Watch the webcast View the document

  • Barclays 28th Annual Global Healthcare Conference

    03/11/2026 | 9:00pm PDT / 12:00am EDT

  • Leerink Partners Global Healthcare Conference

    03/10/2026 | 10:40am PDT / 1:40pm EDT

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
05/14/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
05/12/2026 SCHEDULE 13G SCHEDULE 13G - Description RTF XLS PDF HTML XBRL
05/06/2026 10-Q Quarterly report which provides a continuing view of a company's financial position RTF XLS PDF HTML XBRL
05/05/2026 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
05/04/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/15/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/15/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/14/2026 ARS An annual report to security holders RTF XLS PDF HTML XBRL
04/14/2026 DEFA14A Additional proxy soliciting materials - definitive RTF XLS PDF HTML XBRL
04/14/2026 DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics Names Raj Jampa as New Chief Technology Officer Thumbnail

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Jun 02, 2026 | Products

Read more
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Thumbnail

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

May 27, 2026 | Products | Corporate

Read more
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) Thumbnail

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 26, 2026 | Products

Read more
View all news releases

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report